Thanatophoric dysplasia type 1

Thanatophoric dysplasia type 1 (TD1) is one of the most common lethal skeletal dysplasias, characterized by severe shortening of the limbs, a narrow thorax, and distinctive curved ("telephone receiver") femurs. The name "thanatophoric" derives from the Greek word for "death-bearing," reflecting the typically fatal outcome in the neonatal period. TD1 is caused by heterozygous mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, most commonly the R248C and Y373C missense mutations. These gain-of-function mutations lead to constitutive activation of the FGFR3 receptor, severely disrupting endochondral bone growth. The condition profoundly affects the skeletal system, with features including extreme rhizomelic (proximal) limb shortening, platyspondyly (flattened vertebral bodies), macrocephaly with a prominent forehead, and a very small thoracic cage. The severely constricted chest leads to pulmonary hypoplasia (underdeveloped lungs), which is the primary cause of respiratory failure and death, usually within hours to days after birth. Unlike thanatophoric dysplasia type 2 (which features cloverleaf skull deformity and straight femurs), TD1 is distinguished by its curved long bones and generally does not present with a cloverleaf skull, though mild temporal bossing may occur. Additional features can include redundant skin folds, brachydactyly, and a depressed nasal bridge. Thanatophoric dysplasia type 1 is typically diagnosed prenatally via ultrasound, which reveals severe limb shortening, a small chest, and polyhydramnios. Molecular genetic testing of FGFR3 confirms the diagnosis. The condition is almost invariably lethal in the perinatal period, and management is primarily supportive and palliative. In extremely rare cases where prolonged survival has been achieved with intensive respiratory support, affected individuals develop severe neurological complications including seizures and intellectual disability due to brain abnormalities such as temporal lobe enlargement. There is currently no curative treatment for TD1. Genetic counseling is important for affected families, though nearly all cases arise from de novo (new) mutations with a very low recurrence risk.

Common questions about Thanatophoric dysplasia type 1